长期使用β受体阻滞剂降低TEVAR术后死亡率,术前新启用无获益
基于Vascular Quality Initiative数据库4724例TEVAR患者,分为未用药、术前≤30天启用和长期使用>30天三组。长期使用组围术期死亡、肺部并发症和肠缺血风险降低,但脊髓缺血风险升高;新启用组无显著获益。
要点
- 长期使用β受体阻滞剂与TEVAR术后围术期死亡降低相关
- 长期使用组脊髓缺血风险升高,尤其胸主动脉瘤患者
- 术前≤30天新启用β受体阻滞剂未改善术后结局
核心结论
- 长期使用β受体阻滞剂与TEVAR术后围术期死亡率降低相关,但脊髓缺血风险升高。
- 术前≤30天新启用β受体阻滞剂与术后并发症减少无关。
- B型主动脉夹层患者长期使用β受体阻滞剂额外降低卒中风险且不增加脊髓缺血。
研究设计与样本
- 基于Vascular Quality Initiative数据库的回顾性队列研究,纳入2016-2023年4724例TEVAR患者。
- 患者分为未用药组(1480例)、术前≤30天启用组(778例)和长期使用>30天组(2466例)。
- 采用多变量logistic回归控制混杂因素。
主要发现
- 术前≤30天启用组对比未用药组术后并发症无显著减少。
临床怎么用
- TEVAR术前应继续患者已有的β受体阻滞剂方案,而非术前新启用。
- 长期使用β受体阻滞剂的患者围术期需确保脊髓灌注压的适当管理。
- B型主动脉夹层患者长期使用β受体阻滞剂可能额外获益。
局限性
- 回顾性数据库研究,可能存在未测量混杂因素。
- 需进一步前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Beta-blockers play a pivotal role in reducing perioperative cardiac complications; however, their impact on outcomes following thoracic endovascular aortic repair (TEVAR) remains unknown. Utilizing the Vascular Quality Initiative database, our study aims to uncover the impact and determine the optimal timeframe for initiating beta-blocker therapy prior to TEVAR. METHODS: A total of 4724 TEVAR patients (2016-2023) were grouped as follows: non-beta-blocker users (NBB), beta-blocker initiators ≤30 days prior to procedure (I30), and long-term beta-blocker users for >30 days prior to procedure (L30). Primary outcomes were in-hospital death, stroke, myocardial infarction, and spinal cord ischemia. Secondary outcomes included pulmonary complications, cardiac complications, bowel ischemia, leg ischemia, and prolonged length of stay (≥2 days). A subanalysis was conducted to assess the influence of beta-blocker use by TEVAR indication: type B aortic dissection and thoracic aortic aneurysm. Multivariable logistic regression analysis was performed to control for confounding variables. RESULTS: We identified 1480 NBB (31%), 778 I30 (16%), and 2466 L30 (52%) patients. After adjusting for confounders, I30 patients showed no significant postoperative complication reduction compared with NBB patients. In contrast, L30 patients had reduced odds of perioperative death (adjusted odds ratio [aOR],0.62; 95% confidence interval [CI], 0.40-0.94; P = .025), pulmonary complications (aOR, 0.60; 95% CI, 0.43-0.82; P = .002), and bowel ischemia (aOR, 0.30; 95% CI, 0.12-0.73; P = .009), but had higher rates of spinal cord ischemia (aOR, 1.99; 95% CI, 1.19-3.49; P = .038), compared with NBB patients. When stratified by indication, L30 patients with type B aortic dissection were associated with decreased risks of death (aOR, 0.42; 95% CI, 0.18-0.97; P = .041), stroke (aOR, 0.29; 95% CI, 0.09-0.92; P = .039), and pulmonary complications (aOR, 0.30; 95% CI, 0.13-0.69; P = .004) compared with NBB patients. Among patients with thoracic aortic aneurysm, L30 was associated with higher odds of spinal cord ischemia (aOR, 3.09; 95% CI, 1.34-8.40; P = .014) compared with NBB but had no impact on stroke or death. CONCLUSIONS: Long-term use of beta-blockers was associated with lower perioperative mortality but higher spinal cord ischemia following TEVAR. Patients with type B aortic dissection had the additional benefit of lower stroke rates without increased spinal cord ischemia. In contrast, initiating beta-blockers preoperatively, independent of pathology, was not associated with improved outcomes. Although further prospective studies are necessary, these results indicate that patients should continue their beta-blocker regimen before undergoing TEVAR, and appropriate management of spinal perfusion pressure should be ensured perioperatively.
引用
- Straus S, Farah M, Yin K, et al. Long-term beta blocker use lowers postoperative mortality while initiating beta blockers preoperatively does not improve outcomes in thoracic endovascular aortic repair. J Vasc Surg. 2025. PMID: 40582427. doi:10.1016/j.jvs.2025.06.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。